{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T11:47:46Z","timestamp":1776858466288,"version":"3.51.2"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":16,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.jtct.2026.02.047","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T07:53:43Z","timestamp":1771401223000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Incidence, Recurrence, Timing, and Economic Impact of Infections After CAR T-Cell Therapy: A Real-World Analysis From MarketScan Database"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4842-7551","authenticated-orcid":false,"given":"Mohammed","family":"Zuber","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7279-4418","authenticated-orcid":false,"given":"Shaimaa","family":"Elshafie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4018-0195","authenticated-orcid":false,"given":"Daniel B","family":"Chastain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2452-0556","authenticated-orcid":false,"given":"Chia Jie","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3821-4595","authenticated-orcid":false,"given":"Lorenzo","family":"Villa Zapata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2026.02.047_bib0001","doi-asserted-by":"crossref","unstructured":"June CH, Sadelain M. Chimeric antigen receptor therapy. 2018;379(1):64-73. doi:10.1056\/NEJMra1706169","DOI":"10.1056\/NEJMra1706169"},{"issue":"22","key":"10.1016\/j.jtct.2026.02.047_bib0002","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2024.19462","article-title":"CAR T cells and T-cell therapies for cancer: a translational science review","volume":"332","author":"Brudno","year":"2024","journal-title":"Jama"},{"key":"10.1016\/j.jtct.2026.02.047_bib0003","doi-asserted-by":"crossref","unstructured":"Chen Y-J, Abila B, Mostafa Kamel Y. CAR-T: what is next? 2023;15(3):663.","DOI":"10.3390\/cancers15030663"},{"key":"10.1016\/j.jtct.2026.02.047_bib0004","doi-asserted-by":"crossref","DOI":"10.1177\/0963689720919434","article-title":"Factors associated with costs in chimeric antigen receptor T-cell therapy for patients with relapsed\/refractory B-cell malignancies","volume":"29","author":"Zhu","year":"2020","journal-title":"Cell Transplant"},{"issue":"10254","key":"10.1016\/j.jtct.2026.02.047_bib0005","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet (London, England)"},{"issue":"1","key":"10.1016\/j.jtct.2026.02.047_bib0006","doi-asserted-by":"crossref","first-page":"77.e1","DOI":"10.1016\/j.jtct.2023.10.017","article-title":"Real-world outcomes with chimeric antigen receptor T cell therapies in large B cell lymphoma: a systematic review and meta-analysis","volume":"30","author":"Jacobson","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2026.02.047_bib0007","doi-asserted-by":"crossref","unstructured":"Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. 2017;377(26):2531-2544. doi:10.1056\/NEJMoa1707447","DOI":"10.1056\/NEJMoa1707447"},{"key":"10.1016\/j.jtct.2026.02.047_bib0008","doi-asserted-by":"crossref","unstructured":"Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. 2019;380(1):45-56. doi:10.1056\/NEJMoa1804980","DOI":"10.1056\/NEJMoa1804980"},{"issue":"26","key":"10.1016\/j.jtct.2026.02.047_bib0009","first-page":"3321","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"J Am Soc Hematol"},{"issue":"1","key":"10.1016\/j.jtct.2026.02.047_bib0010","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy\u2014assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nature Rev Clin Oncol"},{"key":"10.1016\/j.jtct.2026.02.047_bib0011","doi-asserted-by":"crossref","unstructured":"Shalabi H, Gust J, Taraseviciute A, et al. Beyond the storm\u2014subacute toxicities and late effects in children receiving CAR T cells. 2021;18(6):363-378.","DOI":"10.1038\/s41571-020-00456-y"},{"issue":"9","key":"10.1016\/j.jtct.2026.02.047_bib0012","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1038\/s41591-024-03084-6","article-title":"A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy","volume":"30","author":"Cordas dos Santos","year":"2024","journal-title":"Nature Med"},{"issue":"1","key":"10.1016\/j.jtct.2026.02.047_bib0013","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy","volume":"131","author":"Hill","year":"2018","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.jtct.2026.02.047_bib0014","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/s41409-022-01756-w","article-title":"Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy","volume":"57","author":"Wudhikarn","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"23","key":"10.1016\/j.jtct.2026.02.047_bib0015","doi-asserted-by":"crossref","first-page":"5312","DOI":"10.1182\/bloodadvances.2021004896","article-title":"Infectious complications of CAR T-cell therapy across novel antigen targets in the first 30 days","volume":"5","author":"Mikkilineni","year":"2021","journal-title":"Blood advances"},{"issue":"10","key":"10.1016\/j.jtct.2026.02.047_bib0016","first-page":"955","article-title":"Best practice considerations by the American Society of Transplant and Cellular Therapy: infection prevention and management after chimeric antigen receptor T cell therapy for hematological malignancies","volume":"30","author":"Shahid","year":"2024","journal-title":"Transplant Cell Ther Off Publ Am Soc Transplant Cell Ther"},{"issue":"7","key":"10.1016\/j.jtct.2026.02.047_bib0017","doi-asserted-by":"crossref","first-page":"404.e1","DOI":"10.1016\/j.jtct.2022.03.021","article-title":"Health care resource utilization and total costs of care among patients with diffuse large B cell lymphoma treated with chimeric antigen receptor T cell therapy in the United States","volume":"28","author":"Keating","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"10","key":"10.1016\/j.jtct.2026.02.047_bib0018","doi-asserted-by":"crossref","first-page":"e296","DOI":"10.1371\/journal.pmed.0040296","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies","volume":"4","author":"von Elm","year":"2007","journal-title":"PLOS Medicine"},{"issue":"1","key":"10.1016\/j.jtct.2026.02.047_bib0019","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000521288","article-title":"Charlson Comorbidity Index: a critical review of clinimetric properties","volume":"91","author":"Charlson","year":"2022","journal-title":"Psychother psychosomat"},{"issue":"5","key":"10.1016\/j.jtct.2026.02.047_bib0020","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"issue":"4","key":"10.1016\/j.jtct.2026.02.047_bib0021","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/cid\/ciy152","article-title":"Cytokine release syndrome grade as a predictive marker for infections in patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with chimeric antigen receptor T cells","volume":"67","author":"Park","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.jtct.2026.02.047_bib0022","doi-asserted-by":"crossref","first-page":"ofaa121","DOI":"10.1093\/ofid\/ofaa121","article-title":"Infectious complications following CD19 chimeric antigen receptor T-cell therapy for children, adolescents, and young adults","volume":"7","author":"Vora","year":"2020","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"10.1016\/j.jtct.2026.02.047_bib0023","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.cmi.2024.11.008","article-title":"Timeline and outcomes of viral and fungal infections after chimeric antigen receptor T-cell therapy: a large database analysis","volume":"31","author":"Sassine","year":"2025","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"10.1016\/j.jtct.2026.02.047_bib0024","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3324\/haematol.2019.238634","article-title":"Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma","volume":"106","author":"Logue","year":"2021","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.jtct.2026.02.047_bib0025","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41408-020-00346-7","article-title":"Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma","volume":"10","author":"Wudhikarn","year":"2020","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jtct.2026.02.047_bib0026","doi-asserted-by":"crossref","unstructured":"Cordeiro A, Bezerra ED, Hirayama AV, et al. Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells. 2020;26(1):26-33.","DOI":"10.1016\/j.bbmt.2019.08.003"},{"issue":"3","key":"10.1016\/j.jtct.2026.02.047_bib0027","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/cid\/ciz1127","article-title":"Invasive mold infections after chimeric antigen receptor-modified T-cell therapy: a case series, review of the literature, and implications for prophylaxis","volume":"71","author":"Haidar","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jtct.2026.02.047_bib0028","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.845540","article-title":"Infectious complications in pediatric, adolescent and young adult patients undergoing CD19-CAR T cell therapy","volume":"12","author":"Maron","year":"2022","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.jtct.2026.02.047_bib0029","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1182\/bloodadvances.2020002732","article-title":"Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma","volume":"5","author":"Baird","year":"2021","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.jtct.2026.02.047_bib0030","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.3390\/curroncol28020117","article-title":"The out-of-pocket cost burden of cancer care-a systematic literature review","volume":"28","author":"Iragorri","year":"2021","journal-title":"Curr Oncol (Toronto, Ont)"},{"key":"10.1016\/j.jtct.2026.02.047_bib0031","doi-asserted-by":"crossref","unstructured":"Hoover A, Reimche P, Watson D, et al. Healthcare cost and utilization for chimeric antigen receptor (CAR) T-cell therapy in the treatment of pediatric acute lymphoblastic leukemia: a commercial insurance claims database analysis. 2024;7(2):e1980. doi:https:\/\/doi.org\/10.1002\/cnr2.1980","DOI":"10.1002\/cnr2.1980"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726001508?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726001508?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T11:09:27Z","timestamp":1776856167000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726001508"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":31,"alternative-id":["S2666636726001508"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.02.047","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incidence, Recurrence, Timing, and Economic Impact of Infections After CAR T-Cell Therapy: A Real-World Analysis From MarketScan Database","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.02.047","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}